Literature DB >> 12747759

Can hTERT peptide (540-548) -specific CD8 T cells recognize and kill tumor cells?

Daniel E Speiser1, Jean-Charles Cerottini, Pedro Romero.   

Abstract

This commentary reviews the data on HLA-A2-restricted CD8 T cells specific for peptide (540-548) derived from hTERT (human telomerase reverse transcriptase). Several studies have reported the successful generation of such T cells (1, 2, 3). However, tumor recognition was observed in some, but not all, studies. More data are required to elucidate whether hTERT peptide (540-548) -specific T cells can indeed recognize and destroy tumor cells. It would be highly useful if telomerase would emerge as a universal tumor antigen that can be targeted in the cancer immunotherapy of HLA-A2 positive patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12747759

Source DB:  PubMed          Journal:  Cancer Immun        ISSN: 1424-9634


  4 in total

1.  Identification of an immunogenic CD8+ T-cell epitope derived from gamma-globin, a putative tumor-associated antigen for juvenile myelomonocytic leukemia.

Authors:  Naoto Hirano; Marcus O Butler; Zhinan Xia; Alla Berezovskaya; Andrew P Murray; Sascha Ansén; Seiji Kojima; Lee M Nadler
Journal:  Blood       Date:  2006-06-15       Impact factor: 22.113

2.  Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase.

Authors:  Maria R Parkhurst; John P Riley; Takehito Igarashi; Yong Li; Paul F Robbins; Steven A Rosenberg
Journal:  Clin Cancer Res       Date:  2004-07-15       Impact factor: 12.531

3.  Telomerase as a tumor-associated antigen for cancer immunotherapy.

Authors:  Kunal P Patel; Robert H Vonderheide
Journal:  Cytotechnology       Date:  2004-06       Impact factor: 2.058

4.  Human melanoma-specific CD8(+) T-cells from metastases are capable of antigen-specific degranulation and cytolysis directly ex vivo.

Authors:  Yolanda D Mahnke; Estelle Devevre; Petra Baumgaertner; Maurice Matter; Nathalie Rufer; Pedro Romero; Daniel E Speiser
Journal:  Oncoimmunology       Date:  2012-07-01       Impact factor: 8.110

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.